Ara
Toplam kayıt 2, listelenen: 1-2
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases
(Elsevier Inc., 2023)
Background: Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), are associated with metabolic abnormalities. Integrative analysis of human clinical data and animal studies ...
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: A randomised, double-blinded, placebo-controlled phase-II trial
(BioMed Central Ltd, 2023)
Background: Alzheimer’s disease (AD) is associated with metabolic abnormalities linked to critical elements of neurodegeneration. We recently administered combined metabolic activators (CMA) to the AD rat model and observed ...